Research At a Glance
- Research Category
- Dermal & Tissue Repair Research
- Peptide Length
- Blend: GHK-Cu (3 aa) + BPC-157 (15 aa) + TB-500 fragment
- Purity
- ≥ 99% (HPLC, per component)
- Published Studies
- 400+ indexed (combined literature)
- Storage
- Lyophilized: 2–8 °C, protected from light. Reconstituted: 2–8 °C, use within 30 days.
Published-study figures are approximate PubMed result counts and indicate the volume of available literature only. Purity reflects third-party analytical testing on the corresponding lot; see the Quality Assurance Center for lot-matched certificates.
Overview
GLOW Blend combines three independently well-studied research peptides in a single formulation: BPC-157 (10mg), TB-500 (10mg), and GHK-Cu (50mg). Each component is studied for a distinct but complementary mechanism relevant to tissue repair and regeneration — BPC-157 for cytoprotective and angiogenic signaling, TB-500 for actin-cytoskeleton-mediated cell migration, and GHK-Cu for collagen synthesis and extracellular matrix gene expression. The blend is formulated for researchers studying combined or overlapping repair pathways rather than any single mechanism in isolation; the characteristic blue tint upon reconstitution comes from the copper coordination complex in GHK-Cu.
Citation
Maquart F.X., et al., FEBS Letters, 1993 (GHK-Cu) / Sikiric P., et al., Pharmaceuticals, 2024 (BPC-157) / Philp D., et al., FASEB J, 2003 (TB-500)
History
Each component peptide has an independent research history: BPC-157 was first described in 1993 from a gastric-juice-derived protein fragment; TB-500 derives from Thymosin Beta-4, characterized as the primary actin-sequestering protein in mammalian cells, with its active LKKTETQ domain mapped in the early 2000s; GHK-Cu was isolated from human plasma in 1973 and characterized for its copper-binding, tissue-signaling properties. Combination formulations like GLOW are a more recent development in the research-peptide market, built on the rationale that the three compounds engage non-overlapping tissue-repair pathways and can be studied together without direct mechanistic redundancy.
Citation
Sikiric P., et al., J Physiol Paris, 1993
Structure
| BPC-157 — CAS # | 137525-51-0 |
|---|---|
| BPC-157 — Molecular Formula | C62H98N16O22 |
| BPC-157 — Molecular Weight | 1419.53 g/mol |
| TB-500 — CAS # | 77591-33-4 |
| TB-500 — Molecular Formula | C212H350N56O78S |
| TB-500 — Molecular Weight | 4963.5 g/mol |
| GHK-Cu — CAS # | 89030-95-5 |
| GHK-Cu — Molecular Formula | C14H24CuN6O4 |
| GHK-Cu — Molecular Weight | 403.92 g/mol |
| Total Blend | 70mg per vial (BPC-157 10mg / TB-500 10mg / GHK-Cu 50mg) |
Research Findings
This three-component blend spans gastrointestinal, vascular, musculoskeletal, and dermal research models, reflecting the combined literature of its individual peptides.
Key Areas of Research
- Angiogenesis: BPC-157 vascular recruitment and VEGFR2 signaling; TB-500 endothelial migration and VEGF upregulation; GHK-Cu capillary density improvement
- Cell migration: TB-500 actin cytoskeleton regulation and cytoskeletal dynamics
- Extracellular matrix: GHK-Cu collagen, elastin, and glycosaminoglycan gene expression
- Tissue protection: BPC-157 cytoprotective signaling across gastrointestinal, vascular, and musculoskeletal models
Summary
Together, the three-peptide combination allows researchers to examine overlapping and independent tissue-repair pathways within a single formulation — angiogenic signaling from two directions (BPC-157 and TB-500), cell-migration biology (TB-500), and collagen/matrix remodeling (GHK-Cu). Each component’s individual literature is well developed; direct combination-arm studies evaluating GLOW as a fixed formulation are comparatively limited, so findings for this profile draw on each peptide’s independent research base.
Citation
Sosne G., et al., FASEB Journal, 2010
References
- Sikiric P., Petek M., Rucman R., et al. (1993). A new gastric juice peptide, BPC. Journal de Physiologie (Paris).
- Philp D., Huff T., Gho Y.S., Hannappel E., Kleinman H.K. (2003). The actin binding site on thymosin beta4 promotes angiogenesis. FASEB Journal.
- Pickart L., Thaler M.M. (1973). Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature New Biology.
- Maquart F.X., et al. (1993). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters.
Source
Component literature available via PubMed — GHK-Cu, BPC-157, and TB-500 tissue repair research .
Certificate of Analysis
Every lot is independently tested and lot-matched. View Certificates of Analysis